References
[1] Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 71(3), 209-249.
[2] Feng, F., Liu, J., Wang, F., Zheng, G., Wang, Q., Liu, S., ... & Zhang, H. (2018). Prognostic value of differentiation status in gastric cancer. BMC cancer, 18(1), 1-6.
[3] Xing, X., Guo, J., Ding, G., Li, B., Dong, B., Feng, Q., ... & Ji, J. (2018). Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients. Oncoimmunology, 7(3), e1356144.
[4] Kang, Y. K., Boku, N., Satoh, T., Ryu, M. H., Chao, Y., Kato, K., ... & Chen, L. T. (2017). Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 390(10111), 2461-2471.
[5] Iwasa, S., Muro, K., Satoh, T., Hironaka, S., Esaki, T., Nishina, T., ... & Watanabe, M. (2019). Phase 1 trial of avelumab (an-ti-PD-L1) in Japanese patients with advanced solid tumors, including dose expansion in patients with gastric or gastroesophageal junction cancer: the JAVELIN Solid Tumor JPN trial. Gastric Cancer, 22(4), 817-827.
[6] Bang, Y. J., Kang, Y. K., Catenacci, D. V., Muro, K., Fuchs, C. S., Geva, R., ... & Chung, H. C. (2019). Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer, 22(4), 828-837.
[7] Alsina, M., Moehler, M., Hierro, C., Guardeño, R., & Tabernero, J. (2016). Immunotherapy for gastric cancer: a focus on immune checkpoints. Targeted oncology, 11(4), 469-477.
[8] Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D., Gupta, S., ... & Bang, Y. J. (2016). Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. The lancet oncology, 17(6), 717-726.
[9] Shitara, K., Özgüroğlu, M., Bang, Y. J., Di Bartolomeo, M., Mandalà, M., Ryu, M. H., ... & Becerra, C. (2018). Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. The Lancet, 392(10142), 123-133.
[10] Chen, L. T., Satoh, T., Ryu, M. H., Chao, Y., Kato, K., Chung, H. C., ... & Boku, N. (2020). A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer, 23(3), 510-519.
[11] Chung, H. C., Ros, W., Delord, J. P., Perets, R., Italiano, A., Shapira-Frommer, R., ... & Leary, A. (2019). Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. Journal of Clinical Oncology, 37(17).
[12] Eigentler, T. K., Hassel, J. C., Berking, C., Aberle, J., Bachmann, O., Grünwald, V., ... & Gutzmer, R. (2016). Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer treatment reviews, 45, 7-18.
[13] Wang, M., Ma, X., Guo, L., & Xia, F. (2017). Safety and efficacy profile of pembrolizumab in solid cancer: pooled reanalysis based on randomized controlled trials. Drug design, development and therapy, 11, 2851.